ASCO GUIDELINES Bundle

Squamous Cell Carcinoma of Unknown Primary Head and Neck

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475503

Contents of this Issue

Navigation

Page 9 of 11

10 Systemic Therapy Figure 2. Diagnosis & Management Algorithm of SCCUP in the Head and Neck (cont'd) Patients with multiple pathologically involved nodes and/or pathologic eveidence of ENE a Additional nodal basins should be considered for dissection depending on the extent of nodal burden. b Specific volumes treated will depend on the clinicopathologic presentation of the patient aer complete work-up. c Consideration may be given to including additional areas in the oropharynx in patients for whom a PET scan was not available or who did not undergo a contralateral tonsillectomy because of the now risk of an occult contralateral tonsillar primary. d Patients presenting with bilateral (AJCC 8th N2) adenopathy and CUP require bilateral treatment of the oropharyngeal mucosa. e Nodal volumes in this scenario should be typical for nasopharygeal management and include bilateral levels II-V including retropharyngeal nodes. Unilateral small volume neck disease Multidisciplinary discussion Definitive surgery Levels IIA, III and IV should be routinely dissected a Patients with a single pathologically positive node without ENE after high-quality neck dissection and no primary tumor identified Adjuvant radiotherapy ± chemotherapy Observation • Equivalent of 60 Gy to the node levels that harbored gross resected disease, and 50 Gy to regions beyond this thought to be at risk of microscopic residual disease. • Nodal regions from which nodes were determined to have pathologic ENE may be considered for higher doses of adjuvant radiation, the equivalent of 60- 66 Gy. May be considered for adjuvant concurrent hemotherapy. Dose • 70 Gy over 7 weeks to gross nodal disease • Approximately 50 Gy in 2 Gy fractions or slightly higher to mucosal regions at-risk of harboring the occult primary site • 40-50 Gy in 2 Gy fractions electively to clinically and radiographically negative nodal regions at risk for microscopic spread of tumor Dose Radiation of mucosal sites should be avoided in clinical scenarios highly suggestive of an occult cutaneous primary SCC Mucosal radiation treatment may be limited to the nasopharynx in clinicopathologic presentation highly suggestive of an occult nasopharyngeal primary e Clinical scenarios Definitive radiotherapy

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Squamous Cell Carcinoma of Unknown Primary Head and Neck